Nonalcoholic fatty liver disease is a risk factor for thiopurine hepatotoxicity in Crohn's disease
Crohn's & Colitis 360
Open Access Publication
Rights and Permissions
Alvin T George, MD, Matthew Glover, MD, Quazim Alayo, MD, Maria Zulfiqar, MD, Daniel R Ludwig, MD, Matthew A Ciorba, MD, Scott McHenry, MD, Parakkal Deepak, MBBS, MS, Nonalcoholic Fatty Liver Disease Is a Risk Factor for Thiopurine Hepatotoxicity in Crohn’s Disease, Crohn's & Colitis 360, Volume 5, Issue 1, January 2023, otad005, https://doi.org/10.1093/crocol/otad005. https://academic.oup.com/crohnscolitis360/article/5/1/otad005/7028375?login=true. © The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact firstname.lastname@example.org.
George, Alvin T; Glover, Matthew; Alayo, Quazim; Zulfiqar, Maria; Ludwig, Daniel R; Ciorba, Matthew A; McHenry, Scott; and Deepak, Parakkal, "Nonalcoholic fatty liver disease is a risk factor for thiopurine hepatotoxicity in Crohn's disease." Crohn's & Colitis 360. 5, 1. otad005 (2023).
ICTS (Institute of Clinical and Translational Sciences)